Jean Stanton Johnson and Johnson

Jean joined Johnson and Johnson in 2008 within the Pharmaceutical Quality Assurance organization after more than 20 years in the health care industry, developing and manufacturing cell based therapies. Jean was responsible for leading the integration of cell and gene therapy regulations into J&J’s Pharm supply chain.

Her current responsibilities are the deployment and maintenance of the R&D compliance program for all GMP aspects within J&J’s Pharmaceutical Sector, which includes the development of the quality and compliance strategies to support all new platforms  in-licensed and/or developed within the Pharmaceutical Sector.

Jean is currently co-chairing the Parenteral Drug Task Force, developing a Technical Report on the development of a manufacturing control strategy for gene and cell therapy products.